JP2012529444A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529444A5 JP2012529444A5 JP2012514348A JP2012514348A JP2012529444A5 JP 2012529444 A5 JP2012529444 A5 JP 2012529444A5 JP 2012514348 A JP2012514348 A JP 2012514348A JP 2012514348 A JP2012514348 A JP 2012514348A JP 2012529444 A5 JP2012529444 A5 JP 2012529444A5
- Authority
- JP
- Japan
- Prior art keywords
- arg
- compound
- lys
- replaced
- cyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 4
- 208000026062 Tissue disease Diseases 0.000 claims 4
- 206010060872 Transplant failure Diseases 0.000 claims 4
- 102000010970 Connexin Human genes 0.000 claims 3
- 108050001175 Connexin Proteins 0.000 claims 3
- 210000003976 gap junction Anatomy 0.000 claims 3
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical group C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000036982 Spinal cord ischaemia Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 230000006020 chronic inflammation Effects 0.000 claims 2
- 230000009843 endothelial lesion Effects 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 102000001189 Cyclic Peptides Human genes 0.000 claims 1
- 108010069514 Cyclic Peptides Proteins 0.000 claims 1
- 101100491597 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-6 gene Proteins 0.000 claims 1
- 230000008568 cell cell communication Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09007772A EP2260859A1 (en) | 2009-06-12 | 2009-06-12 | Compounds acting as peptide gap junction modulators and their uses |
| EP09007772.8 | 2009-06-12 | ||
| US18783909P | 2009-06-17 | 2009-06-17 | |
| US61/187,839 | 2009-06-17 | ||
| PCT/DK2010/000092 WO2010142293A1 (en) | 2009-06-12 | 2010-06-11 | Compounds acting as peptide gap junction modulators, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012529444A JP2012529444A (ja) | 2012-11-22 |
| JP2012529444A5 true JP2012529444A5 (cg-RX-API-DMAC7.html) | 2013-08-01 |
Family
ID=41217722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012514348A Pending JP2012529444A (ja) | 2009-06-12 | 2010-06-11 | ペプチドギャップ結合調節因子として作用する化合物及びその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20120264693A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2260859A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012529444A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010142293A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201512139D0 (en) * | 2015-07-10 | 2015-08-19 | Zealand Pharma As | Methods of treatment |
| US20190054184A1 (en) * | 2016-02-12 | 2019-02-21 | The General Hospital Corporation | Targeting Macrophages to Modulate Electrical Conduction in the Heart |
| EP4291178A1 (en) * | 2021-02-10 | 2023-12-20 | Breye Therapeutics ApS | Danegaptide for use in the treatment or prevention of a kidney disease |
| GB202310195D0 (en) * | 2023-07-03 | 2023-08-16 | Hastings Nataly | Method for mitigating symptoms of neurological condition and a system therefor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350741A (en) | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
| PT1226160E (pt) | 2000-02-23 | 2005-04-29 | Zealand Pharma As | Novos peptidos antiarritmicos |
| EP1978988A4 (en) * | 2006-01-13 | 2009-11-04 | Univ New York State Res Found | PEPTIDE-BASED REGULATION OF GAP-JUNCTIONS |
| WO2009012224A2 (en) * | 2007-07-13 | 2009-01-22 | The Research Foundation Of State University Of New York | Peptide-based regulation of gap junctions |
| JP2010533690A (ja) * | 2007-07-15 | 2010-10-28 | ジーランド・ファーマ・ア／エス | ペプチドギャップ結合モジュレーター |
-
2009
- 2009-06-12 EP EP09007772A patent/EP2260859A1/en not_active Ceased
-
2010
- 2010-06-11 US US13/377,773 patent/US20120264693A1/en not_active Abandoned
- 2010-06-11 WO PCT/DK2010/000092 patent/WO2010142293A1/en not_active Ceased
- 2010-06-11 EP EP10734651A patent/EP2440229A1/en not_active Withdrawn
- 2010-06-11 JP JP2012514348A patent/JP2012529444A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113880915B (zh) | 用于修复黏膜损伤或皮肤创伤的多肽及其应用 | |
| WO2010129864A3 (en) | Methods and compositions for studying, imaging, and treating pain | |
| RU2007131504A (ru) | Пептиды, обладающие агонистической активностью в отношении рецептора нейропептида-2-(y2r) | |
| MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
| CA2777746A1 (en) | Benzoimidazole compounds and uses thereof | |
| JP2008510758A5 (cg-RX-API-DMAC7.html) | ||
| JP2009544585A5 (cg-RX-API-DMAC7.html) | ||
| WO2011159693A2 (en) | Oral treatment of digital ischemic lesions | |
| JP2012529444A5 (cg-RX-API-DMAC7.html) | ||
| JP2014508758A5 (cg-RX-API-DMAC7.html) | ||
| JP2010514834A5 (cg-RX-API-DMAC7.html) | ||
| JP2012508256A5 (cg-RX-API-DMAC7.html) | ||
| WO2007096396A3 (en) | Methods for treating autoimmune or demyelinating diseases | |
| JP2008534503A5 (cg-RX-API-DMAC7.html) | ||
| EP4308167A1 (en) | New peptide conjugates | |
| JP2010506844A5 (cg-RX-API-DMAC7.html) | ||
| EA200602016A1 (ru) | ПОРОШКОВЫЕ КОМПОЗИЦИИ ДЛЯ ИНГАЛЯЦИИ, СОДЕРЖАЩИЕ ЭНАНТИОМЕРНОЧИСТЫЕ β-АГОНИСТЫ | |
| GB201119910D0 (en) | Self-assembling peptides | |
| WO2024260465A1 (en) | New multi-functional oligopeptides | |
| JP2010524910A5 (cg-RX-API-DMAC7.html) | ||
| RU2012107483A (ru) | Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| WO2018038966A1 (en) | Pharmaceutical compositions for inducing phenotypic reversion of a cell and regeneration of compromised tissue | |
| WO2007070385A3 (en) | Treatment of multiple sclerosis using interferon-tau | |
| JPWO2020234781A5 (cg-RX-API-DMAC7.html) |